Global Healthcare Weekly

In our global healthcare weekly, we focus on identifiying key stock catalysts for biotech companies this week. Atara Biotherapeutics (NASDAQ: ATRA) with a market cap of around $41.8 million, focuses on developing T-cell immunotherapies for cancers and autoimmune diseases. The firm’s lead candidate, The FDA has set a PDUFA priority review date for January 15, 2025. Tabelecleucel has breakthrough therapy designation (BTD) for this rare indication, and approval could solidify Atara’s pre Axsome Therapeutics Inc. (NASDAQ: AXSM) is a late-stage biopharmaceutical company with a market cap of $3.88 billion, developing treatments for central nervous system disorders. The firm ha A key upcoming catalyst is the PDUFA decision for AXS-07, a combination of meloxicam and rizatriptan for the treatment of migraines, expected on January 31, 2025. AXS-07 has shown potential SpringWorks Therapeutics Inc. (NASDAQ: SWTX) with a market cap of about $1.93 billion, is focused on targeted oncology therapies. Its pipeline includes investigational treatments for rare d Mirdametinib is being developed for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas, a rare genetic disorder. The FDA has granted priority review with a PDUFA d Mesoblast Limited (NASDAQ: MESO) is a regenerative medicine company focused on developing cellular therapies. With a market cap of approximately $1.05 billion, the firm is working to commer A key upcoming catalyst is the PDUFA date for RYONCIL, scheduled for January 7, 2025. The FDA accepted the resubmission of the BLA on July 23, 2024. This product, if approved, could address